Entity

Time filter

Source Type


Canady J.,Jerome Canady Research Institute for Advanced Biological and Technological science | Shashurin A.,George Washington University | Wiley K.,Jerome Canady Research Institute for Advanced Biological and Technological science | Fisch N.J.,Princeton University | Keidar M.,George Washington University
Plasma Medicine | Year: 2013

Plasma and injury properties produced by US Medical Innovations (USMI) elec­trosurgical systems were characterized using an explant pig’s liver samples. It was observed that plasma length, tissue temperature, and injury size increases with applied power increase. Transition from conventional to argon coagulation mode (<0.5 L/min) leads to redistribution of the discharge power over the larger tissue area causing abrupt decrease of injury depth and increase of eschar diameter. Flow rate is not a primary factor affecting the tissue temperature. The depth and diameter of injury was minimal for the case of hybrid argon plasma cut opera­tional mode. © 2013 by Begell House, Inc. Source


Ratovitski E.A.,George Washington University | Ratovitski E.A.,Johns Hopkins University | Cheng X.,George Washington University | Yan D.,George Washington University | And 5 more authors.
Plasma Processes and Polymers | Year: 2014

Cold atmospheric plasma (CAP) has just recently been showing promising anti-cancer activities supported by ability to induce cell death via apoptosis and cell cycle arrest leading to tumor cell destruction in vitro, and in vivo. Several studies showed the ability of CAP-activated media to modulate the tumor cell environment a link between the generation of reactive oxygen species/reactive nitrogen species and cancer cell death following CAP treatment. Targeting cancer cells through ROS-mediated mechanisms has become an attractive strategy for effective and selective cancer treatment by exploiting the aberrant redox characteristics of cancer cells. These effects support the potential direct (CAP) and indirect (CAP-activated media) applications for adjuvant anti-cancer therapeutics, in a combination with the chemo-, radio-, and nano-therapies. © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. Source


Yan D.,George Washington University | Sherman J.H.,George Washington University | Cheng X.,George Washington University | Ratovitski E.,Johns Hopkins University | And 2 more authors.
Applied Physics Letters | Year: 2014

Cold atmospheric plasma (CAP) constitutes a "cocktail" of various reactive species. Accumulating evidence shows the effectiveness of CAP in killing cancer cells and decreasing the tumor size, which provides a solid basis for its potential use in cancer treatment. Currently, CAP is mainly used to directly treat cancer cells and trigger the death of cancer cells via apoptosis or necrosis. By altering the concentration of fetal bovine serum in Dulbecco's modified Eagle's medium and the temperature to store CAP stimulated media, we demonstrated controllable strategies to harness the stimulated media to kill glioblastoma cells in vitro. This study demonstrated the significant role of media in killing cancer cells via the CAP treatment. © 2014 AIP Publishing LLC. Source

Discover hidden collaborations